Stifel Nicolaus reissued their buy rating on shares of Horizon Pharma PLC (NASDAQ:HZNP) in a research note published on Sunday morning. The firm currently has a $20.00 price target on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently weighed in on the company. ValuEngine raised Horizon Pharma PLC from a hold rating to a buy rating in a report on Monday, October 16th. Piper Jaffray Companies set a $18.00 price target on Horizon Pharma PLC and gave the company a buy rating in a research note on Sunday, October 15th. Zacks Investment Research downgraded Horizon Pharma PLC from a hold rating to a sell rating in a research note on Tuesday, October 10th. Jefferies Group LLC reaffirmed a buy rating and issued a $16.00 price target on shares of Horizon Pharma PLC in a research note on Thursday, October 5th. Finally, Cowen and Company reaffirmed a buy rating on shares of Horizon Pharma PLC in a research note on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $18.00.
Horizon Pharma PLC (NASDAQ HZNP) opened at 13.75 on Friday. The stock has a 50 day moving average of $13.19 and a 200-day moving average of $12.65. The firm’s market cap is $2.25 billion. Horizon Pharma PLC has a 52 week low of $9.45 and a 52 week high of $21.98.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The company had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. During the same quarter last year, the firm earned $0.56 earnings per share. The company’s revenue was up 12.5% on a year-over-year basis. Analysts expect that Horizon Pharma PLC will post $1.07 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Stifel Nicolaus Reaffirms Buy Rating for Horizon Pharma PLC (HZNP)” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/2982130/stifel-nicolaus-reaffirms-buy-rating-for-horizon-pharma-plc-hznp.html.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in Horizon Pharma PLC by 68,479.5% in the first quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock valued at $196,001,000 after buying an additional 13,241,875 shares during the period. Paulson & CO. Inc. acquired a new position in Horizon Pharma PLC in the second quarter valued at approximately $58,584,000. Dimensional Fund Advisors LP lifted its stake in Horizon Pharma PLC by 119.4% in the second quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock valued at $74,373,000 after buying an additional 3,409,411 shares during the period. William Blair Investment Management LLC acquired a new position in Horizon Pharma PLC in the second quarter valued at approximately $23,557,000. Finally, Balyasny Asset Management LLC acquired a new position in Horizon Pharma PLC in the second quarter valued at approximately $13,958,000. Institutional investors and hedge funds own 82.68% of the company’s stock.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.